Melitracen: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
No edit summary
Line 3: Line 3:
| verifiedrevid = 462248286
| verifiedrevid = 462248286
| IUPAC_name = 3-(10,10-dimethylanthracen-9(10''H'')-ylidene)-''N'',''N''-dimethylpropan-1-amine
| IUPAC_name = 3-(10,10-dimethylanthracen-9(10''H'')-ylidene)-''N'',''N''-dimethylpropan-1-amine
| image = Melitracen-structure.png
| image =  


<!--Clinical data-->
<!--Clinical data-->
Line 44: Line 44:
| StdInChIKey = GWWLWDURRGNSRS-UHFFFAOYSA-N
| StdInChIKey = GWWLWDURRGNSRS-UHFFFAOYSA-N
}}
}}
 
__NOTOC__
{{SI}}
{{CMG}}
== Overview ==
'''Melitracen''' ('''Adaptol''', '''Dixeran''', '''Melixeran''', '''Thymeol''', '''Trausabun''') is a [[tricyclic antidepressant]] (TCA) marketed in [[Europe]] and [[Japan]] by [[Lundbeck]] and [[Takeda]], respectively, for the treatment of [[Major depressive disorder|depression]]  and [[anxiety]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = http://books.google.com/?id=5GpcTQD_L2oC&lpg=PA643&dq=melitracen&pg=PA643#v=onepage&q=}}</ref><ref name="isbn0-412-54090-8">{{cite book | author = | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | pages = | isbn = 0-412-54090-8 | oclc = | doi = | url = http://books.google.com/?id=x2Su3GKCvtsC&lpg=PA4129&dq=melitracen&pg=PA4129#v=onepage&q= | author1 = Hall, Chapman and | author2 = Chemical Abstracts Service, American Chemical Society | author3 = Rhodes, P. H}}</ref><ref name="isbn0-911910-13-1">{{cite book | author = O'Neil, Maryadele J. | title = The Merck index: an encyclopedia of chemicals, drugs, and biologicals | publisher = Merck Research Laboratories | location = Rahway, NJ | year = 2001 | pages = | isbn = 0-911910-13-1 | oclc = | doi = | url = }}</ref><ref name="isbn3-527-31058-4">{{cite book | author = José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | pages = | isbn = 3-527-31058-4 | oclc = | doi = | url = http://books.google.com/?id=yXD4QA-Y_Z0C&lpg=PA248&dq=melitracen&pg=PA248#v=onepage&q=}}</ref> In addition to single drug preparations, it is also available as [[Flupentixol/melitracen|Deanxit]], a combination product containing both melitracen and [[flupentixol]].<ref name="isbn3-7692-2114-1">{{cite book | author = | title = European Drug Index, 4th Edition | publisher = CRC Press | location = Boca Raton | year = 1998 | pages = | isbn = 3-7692-2114-1 | oclc = | doi = | url = http://books.google.com/?id=HiSdvzs2pPAC&lpg=PA380&dq=melitracen&pg=PA327#v=onepage&q=melitracen | author1 = Muller, Niels F | author2 = Dessing, Rudolf P | author3 = Pharmacy, European Society of Clinical}}</ref><ref name="pmid6670581">{{cite journal | author = Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A | title = Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol | journal = Acta Psychiatrica Belgica | volume = 83 | issue = 5 | pages = 525–39 | year = 1983 | pmid = 6670581 | doi = | url = }}</ref><ref name="pmid3917005">{{cite journal | author = Bin Yaacob H | title = Flupenthixol and Melitracen in the management of trigeminal neuralgia | journal = Dental Journal of Malaysia | volume = 8 | issue = 2 | pages = 37–8 |date=April 1985 | pmid = 3917005 | doi = | url = }}</ref><ref name="pmid18331614">{{cite journal | author = Hashash JG | title = Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia | journal = Alimentary Pharmacology & Therapeutics | volume = 27 | issue = 11 | pages = 1148–55 |date=June 2008 | pmid = 18331614 | doi = 10.1111/j.1365-2036.2008.03677.x | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2008&volume=27&issue=11&spage=1148 | author-separator = , | author2 = Abdul-Baki H | author3 = Azar C | display-authors = 3 | last4 = Elhajj | first4 = I. I. | last5 = El Zahabi | first5 = L. | last6 = Chaar | first6 = H. F. | last7 = Sharara | first7 = A. I.}}</ref>
'''Melitracen''' ('''Adaptol''', '''Dixeran''', '''Melixeran''', '''Thymeol''', '''Trausabun''') is a [[tricyclic antidepressant]] (TCA) marketed in [[Europe]] and [[Japan]] by [[Lundbeck]] and [[Takeda]], respectively, for the treatment of [[Major depressive disorder|depression]]  and [[anxiety]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = http://books.google.com/?id=5GpcTQD_L2oC&lpg=PA643&dq=melitracen&pg=PA643#v=onepage&q=}}</ref><ref name="isbn0-412-54090-8">{{cite book | author = | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | pages = | isbn = 0-412-54090-8 | oclc = | doi = | url = http://books.google.com/?id=x2Su3GKCvtsC&lpg=PA4129&dq=melitracen&pg=PA4129#v=onepage&q= | author1 = Hall, Chapman and | author2 = Chemical Abstracts Service, American Chemical Society | author3 = Rhodes, P. H}}</ref><ref name="isbn0-911910-13-1">{{cite book | author = O'Neil, Maryadele J. | title = The Merck index: an encyclopedia of chemicals, drugs, and biologicals | publisher = Merck Research Laboratories | location = Rahway, NJ | year = 2001 | pages = | isbn = 0-911910-13-1 | oclc = | doi = | url = }}</ref><ref name="isbn3-527-31058-4">{{cite book | author = José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | pages = | isbn = 3-527-31058-4 | oclc = | doi = | url = http://books.google.com/?id=yXD4QA-Y_Z0C&lpg=PA248&dq=melitracen&pg=PA248#v=onepage&q=}}</ref> In addition to single drug preparations, it is also available as [[Flupentixol/melitracen|Deanxit]], a combination product containing both melitracen and [[flupentixol]].<ref name="isbn3-7692-2114-1">{{cite book | author = | title = European Drug Index, 4th Edition | publisher = CRC Press | location = Boca Raton | year = 1998 | pages = | isbn = 3-7692-2114-1 | oclc = | doi = | url = http://books.google.com/?id=HiSdvzs2pPAC&lpg=PA380&dq=melitracen&pg=PA327#v=onepage&q=melitracen | author1 = Muller, Niels F | author2 = Dessing, Rudolf P | author3 = Pharmacy, European Society of Clinical}}</ref><ref name="pmid6670581">{{cite journal | author = Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A | title = Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol | journal = Acta Psychiatrica Belgica | volume = 83 | issue = 5 | pages = 525–39 | year = 1983 | pmid = 6670581 | doi = | url = }}</ref><ref name="pmid3917005">{{cite journal | author = Bin Yaacob H | title = Flupenthixol and Melitracen in the management of trigeminal neuralgia | journal = Dental Journal of Malaysia | volume = 8 | issue = 2 | pages = 37–8 |date=April 1985 | pmid = 3917005 | doi = | url = }}</ref><ref name="pmid18331614">{{cite journal | author = Hashash JG | title = Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia | journal = Alimentary Pharmacology & Therapeutics | volume = 27 | issue = 11 | pages = 1148–55 |date=June 2008 | pmid = 18331614 | doi = 10.1111/j.1365-2036.2008.03677.x | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2008&volume=27&issue=11&spage=1148 | author-separator = , | author2 = Abdul-Baki H | author3 = Azar C | display-authors = 3 | last4 = Elhajj | first4 = I. I. | last5 = El Zahabi | first5 = L. | last6 = Chaar | first6 = H. F. | last7 = Sharara | first7 = A. I.}}</ref>


Line 66: Line 69:
{{Tricyclics}}
{{Tricyclics}}


[[Category:Drug]]
[[Category:Tricyclic antidepressants]]
[[Category:Tricyclic antidepressants]]
[[Category:Anthracenes]]
[[Category:Anthracenes]]

Revision as of 12:57, 13 April 2015

Melitracen
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, IM
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H25N
Molar mass291.43 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Melitracen

Articles

Most recent articles on Melitracen

Most cited articles on Melitracen

Review articles on Melitracen

Articles on Melitracen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Melitracen

Images of Melitracen

Photos of Melitracen

Podcasts & MP3s on Melitracen

Videos on Melitracen

Evidence Based Medicine

Cochrane Collaboration on Melitracen

Bandolier on Melitracen

TRIP on Melitracen

Clinical Trials

Ongoing Trials on Melitracen at Clinical Trials.gov

Trial results on Melitracen

Clinical Trials on Melitracen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Melitracen

NICE Guidance on Melitracen

NHS PRODIGY Guidance

FDA on Melitracen

CDC on Melitracen

Books

Books on Melitracen

News

Melitracen in the news

Be alerted to news on Melitracen

News trends on Melitracen

Commentary

Blogs on Melitracen

Definitions

Definitions of Melitracen

Patient Resources / Community

Patient resources on Melitracen

Discussion groups on Melitracen

Patient Handouts on Melitracen

Directions to Hospitals Treating Melitracen

Risk calculators and risk factors for Melitracen

Healthcare Provider Resources

Symptoms of Melitracen

Causes & Risk Factors for Melitracen

Diagnostic studies for Melitracen

Treatment of Melitracen

Continuing Medical Education (CME)

CME Programs on Melitracen

International

Melitracen en Espanol

Melitracen en Francais

Business

Melitracen in the Marketplace

Patents on Melitracen

Experimental / Informatics

List of terms related to Melitracen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Melitracen (Adaptol, Dixeran, Melixeran, Thymeol, Trausabun) is a tricyclic antidepressant (TCA) marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety.[1][2][3][4] In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol.[5][6][7][8]

The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.[9][10]

See also

References

  1. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  2. ↑ Hall, Chapman and; Chemical Abstracts Service, American Chemical Society; Rhodes, P. H (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
  3. ↑ O'Neil, Maryadele J. (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
  4. ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  5. ↑ Muller, Niels F; Dessing, Rudolf P; Pharmacy, European Society of Clinical (1998). European Drug Index, 4th Edition. Boca Raton: CRC Press. ISBN 3-7692-2114-1.
  6. ↑ Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica. 83 (5): 525–39. PMID 6670581.
  7. ↑ Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia. 8 (2): 37–8. PMID 3917005.
  8. ↑ Hashash JG; Abdul-Baki H; Azar C; et al. (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics. 27 (11): 1148–55. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614. Unknown parameter |author-separator= ignored (help)
  9. ↑ Aronson, Jeffrey Kenneth (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 0-444-53266-8.
  10. ↑ Author Unknown (1970). Ann Reports Medicinal Chem V5 (v. 5). Boston: Academic Press. ISBN 0-12-040505-9.


Template:Antidepressants Template:Anxiolytics

Template:Tricyclics


Template:Nervous-system-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Melitracen&oldid=1086372"